F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comPiramal Pharma Ltd, a leading player in the Indian pharmaceutical industry, offers a wide range of products and services in contract development, manufacturing, and consumer healthcare. As of now, the stock is trading at ₹210.00, with a market capitalization of ₹27,181 crore. In this article, we will analyze Piramal Pharma’s current performance, shareholding structure, and future share price targets from 2025 to 2030.
Here’s a snapshot of the latest performance metrics for Piramal Pharma Ltd:
Open Price: ₹210.00
Previous Close: ₹208.61
Volume: 4,434,331 shares
Value (Lacs): ₹9,091.71
VWAP (Volume Weighted Average Price): ₹207.51
Beta: 0.74
Market Capitalization: ₹27,181 Crore
High: ₹210.50
Low: ₹204.50
Upper Circuit Limit: ₹250.33
Lower Circuit Limit: ₹166.88
52-Week High: ₹307.90
52-Week Low: ₹136.10
Face Value: ₹10
All-Time High: ₹307.90
All-Time Low: ₹63.10
Currently, Piramal Pharma's share price is witnessing moderate movement with a recent high of ₹210.50 and a low of ₹204.50. The 52-week price range of ₹136.10 to ₹307.90 indicates significant volatility and a wide potential for growth or correction based on market sentiment and business performance.
Understanding the ownership structure gives a better picture of investor confidence and market dynamics:
Promoters: 34.95%
Foreign Institutions: 31.49%
Retail and Others: 18.78%
Mutual Funds: 12.73%
Other Domestic Institutions: 2.05%
A healthy institutional interest, including mutual funds and foreign investors, points to the confidence in the company’s long-term prospects. The promoter holding of 34.95% shows significant skin in the game, providing stability.
Based on current valuations, industry outlook, and financial fundamentals, here are the projected share price targets for Piramal Pharma Ltd from 2025 to 2030:
| Year | Share Price Target (₹) |
|---|---|
| 2025 | 210 – 250 |
| 2026 | 250 – 295 |
| 2027 | 295 – 340 |
| 2028 | 340 – 390 |
| 2029 | 390 – 450 |
| 2030 | 450 – 525 |
In 2025, the stock is expected to range between ₹210 and ₹250. This growth may be driven by:
Expansion in global CDMO operations
Increased export opportunities for complex generics
Recovery from past underperformance and improved investor confidence
By 2026, the company could witness further appreciation in its stock price, possibly reaching ₹295. The following factors would contribute:
Growth in domestic OTC business
Higher utilization of manufacturing capacities
Improving EBITDA margins and return ratios
As we move into 2027, share prices may climb to ₹340 due to:
Stronger pipeline of differentiated products
Successful regulatory approvals in key global markets
Enhanced focus on specialty pharma segments
In 2028, the momentum is expected to continue with price targets in the range of ₹340 to ₹390, driven by:
Strategic partnerships and joint ventures
Expanded distribution in emerging markets
Integration of AI and digital tools in R&D and manufacturing
By 2029, share price could reach between ₹390 and ₹450 due to:
Continued expansion in CRAMS (Contract Research and Manufacturing Services)
Consistent improvement in financial metrics
Increased market share in key therapeutic areas
Looking ahead to 2030, Piramal Pharma Ltd could potentially trade between ₹450 and ₹525. The long-term growth will be supported by:
Global recognition as a reliable CDMO partner
Successful diversification into newer high-margin segments
Sustainable financial growth and return on capital employed
Several factors will likely shape the company’s share price trajectory in the coming years:
Industry Tailwinds: Rising demand for outsourced pharma manufacturing
Research & Development: Continued innovation in high-value generics and niche therapies
Regulatory Landscape: Smooth handling of FDA and other global compliances
Financial Health: Revenue visibility and reduced debt levels
Global Expansion: Strategic market entries in the US, Europe, and Asia
Despite the strong potential, there are certain risks investors should keep in mind:
Regulatory Setbacks: Any non-compliance with global regulators like the USFDA
Competitive Pressure: Growing competition in generics and CDMO space
Currency Fluctuations: Global exposure makes earnings sensitive to forex movements
Raw Material Dependency: Heavily reliant on China for APIs may impact margins
The projected share price target for Piramal Pharma in 2025 is between ₹210 and ₹250, supported by operational recovery and growth in contract manufacturing.
A balanced shareholding mix with institutional support and promoter stake of 34.95% suggests moderate volatility and decent governance oversight.
The major drivers include:
Expansion of CDMO services
Growth in consumer healthcare division
Global partnerships and exports
Investment in R&D
Piramal Pharma holds long-term potential in the growing pharma outsourcing space. However, investors should consider regulatory and operational risks before investing.
Piramal Pharma Ltd is steadily positioning itself as a strong contender in the global pharma and CDMO market. With consistent operational improvements, institutional backing, and a strategic growth roadmap, the company’s share price is likely to witness healthy appreciation from 2025 to 2030. While the growth outlook is promising, prudent investors must weigh the associated risks before making investment decisions.
Register & Login